Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 1.00 |
| ▸ | STK17B | O94768 | 4/20 | 0.67 |
| ▸ | TOP2A | P11388 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | AURKA | O14965 | 3/20 | 0.56 |
| ▸ | GSK3B | P49841 | 3/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.56 |
| ▸ | BLK | P51451 | 2/20 | 0.56 |
| ▸ | TEK | Q02763 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | ITK | Q08881 | 2/20 | 0.56 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.56 |
| ▸ | DAPK2 | Q9UIK4 | 2/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256999 | 1.00 | TOP1 (1.00) | TOP1STK17BTOP2AMEN1KMT2A | |
| SCHEMBL29406646 | 0.88 | TOP1 (0.78) | TOP1STK17BTOP2AMEN1KMT2A | |
| SCHEMBL4267530 | 0.85 | TOP1 (0.76) | TOP1STK17BTOP2AMEN1KMT2A | |
| SCHEMBL4267528 | 0.85 | TOP1 (0.76) | TOP1STK17BTOP2AMEN1KMT2A | |
| SCHEMBL4264851 | 0.84 | TOP1 (0.73) | TOP1STK17BMEN1KMT2ARECQL | |
| SCHEMBL4264849 | 0.84 | TOP1 (0.73) | TOP1STK17BMEN1KMT2ARECQL | |
| SCHEMBL30337058 | 0.80 | STK17B (1.00) | TOP1STK17BMEN1KMT2ARECQL | |
| Isoaurostatin SCHEMBL15426107 | 0.76 | MAOA (0.63) | TOP1STK17BTOP2AMEN1KMT2A | |
| Isoaurostatin SCHEMBL29551912 | 0.76 | MAOA (0.63) | TOP1STK17BTOP2AMEN1KMT2A | |
| SCHEMBL3676919 | 0.76 | TOP1 (0.70) | TOP1TOP2AGAAEGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | TOP1 1758/4885STK17B 2724/4885TOP2A 1419/4885 |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | TOP1 1758/4885STK17B 2724/4885TOP2A 1419/4885 |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | TOP1 1758/4885STK17B 2724/4885TOP2A 1419/4885 |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | TOP1 1758/4885STK17B 2724/4885TOP2A 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.